Comparison
Melanotan II vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
121062-08-6
2179963-22-7
Molecular weight
1024.18 g/mol
4727 g/mol
Half-life
1 h
168 h
Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
5
2
of which in humans
5
2
Effects recorded
4
3
Open conflicts
0
0
Documented adverse events
3
2